Cd47 asco. ALX148 (A) is a fusion protein comprised ...
Cd47 asco. ALX148 (A) is a fusion protein comprised of a high affinity CD47 blocker linked to an Background: CD47, an immune checkpoint overexpressed by tumor cells, plays a crucial role in evading the antitumor immune response. DSP107 blocks the CD47:SIRPα 'don't eat me' signaling axis on phagocytes and promotes innate anticancer immunity. This abstract 7507Background: Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and don’t eat me signal on cancers. Akeso revealed that the FDA has approved their IND for CD47 Monoclonal Antibody (AK117) combined with Azacitidine for treating Myelodysplastic Syndromes. AK117, an IgG4 monoclonal antibody (mAb) targeting CD47, has Background AK117 is a novel humanized IgG4 monoclonal antibody (mAb) targeting CD47, a macrophage immune checkpoint and ‘don’t eat me’ signal that allows tumor cells to evade immune CHICAGO, June 2, 2025 /PRNewswire/ -- ImmuneOncia Therapeutics, Inc. 然而，在过去两年时间里，全球范围内不少药企都在CD47靶向药物的研发上折戟。 作为CD47靶点先行者的吉利德，其CD47单抗Magrolimab的两个核心临床试验 About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology ImmuneOncia Therapeutics shared interim results from its clinical trial of IMC-002 for HCC, showcasing a potential new path for treatment at ASCO 2025. It induces tumor phagocytosis and eliminates Evorpacept is a differentiated CD47 blocker that works in combination to spare healthy cells and deliver cancer cells for macrophage destruction ASCO GI 2025 ASPEN-06 is a global, randomized Phase CD47 blockade effectively stimulates macrophage-mediated phagocytosis of AML cells, and when combined with azacitidine (AZA), it synergistically enhances the Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer. A Phase 1 Study of ALX148, a CD47 Blocker, Alone and in Combination with Established Anti-Cancer Antibodies in Patients with Advanced Malignancy and Non Hodgkin Lymphoma Nehal Lakhani1, 2525Background: Hu5F9-G4 is a humanized monoclonal antibody targeting CD47, a “don’t eat me” signal on cancer cells, that stimulates tumor cell phagocytosis and activates an anti-tumor T-cell Eigenschaften CD47 bindet Thrombospondin-1 auf Thrombozyten. Innate and adaptive cytokine modulation was observed. This is an ASCO Meeting Abstract from e14513Background: CD47 provides a potent “do not eat me” signal that allows the tumor to escape removal by the innate immune system. CD47 plays an important role in suppressing phagocytosis through binding to transmembrane Background: CD47 belongs to the immunoglobulin superfamily and is overexpressed in many tumor types. This blockade induces Based on the high ORR in patients with CD47 overexpression on cell membranes, the biomarker application strategy will likely be valid in large-scale clinical trials," In the 48 hours after filing for a $115 million IPO, immuno-oncology developer Forty Seven unveiled first-in-human data for its CD47-targeting monoclonal antibody at the American Society of The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win. DSP107 is unique in that it takes advantage of CD47 expression to drive immune cells into the tumor. CD47 blockade induces tumor phagocytosis and eliminates 7020Background: Magrolimab is a monoclonal antibody blocking CD47, a “don’t eat me” signal overexpressed on cancer cells such as acute myeloid leukemia (AML). Expressed by multiple tumor types, CD47 binds to signal regulatory protein a (SIRPa) on phagocytes, including Despite magrolimab’s latest flop, efforts to target CD47 continue. In addition, we have shown that anti-CD47 antibody treatment selectively increases the ability of macrophages to prime and activate cytotoxic T lymphocytes, which may limit tumor growth beyond Background: CD47, an immune checkpoint overexpressed by tumor cells, plays a crucial role in evading the antitumor immune response. MIL95 is a humanized, anti-CD47 lgG4 monoclonal antibody Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study. AK117, an IgG4 monoclonal antibody (mAb) targeting CD47, has Background: CD47, an immune checkpoint overexpressed by tumor cells, plays a crucial role in evading the antitumor immune response. 1 Tumors upregulate CD47 to evade the immune response. A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC. The SIRPα arm selectively targets CD47 overexpressed on tumor 7009Background: Hu5F9-G4 (5F9) is an antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancers. A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. At the same time, CD47-specific binding of DSP107 enables activation of the Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a 3064Background: CD47 is a transmembrane protein that acts as a “Don’t Eat Me” signal to evade immune recognition. [1] Es ist glykosyliert und phosphoryliert. It is overexpressed in multiple cancer subtypes and is associated with poor - KAHR Bio will present Phase 2 data on DSP107, a first-in-class bi-specific 4-1BB T-cell engager, combined with atezolizumab for third-line microsatellite stable colorectal cancer at ASCO 2025. 2514Background: CD47 is a myeloid checkpoint upregulated by tumor cells to evade the host’s immune response. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47 转载自Umabs DB2024年6月的ASCO期间， 宜明昂科 更新了SIRPα-Fc融合蛋白IMM01最新的二期临床数据，同时也宣告近期已经启动了包括 MDS 、CMML Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats. Editor's Note: The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. 8586Background: Blockade of CD47, an immunoglobulin overexpressed on solid tumor cells that inhibits macrophage phagocytosis, is a promising anti-cancer immunotherapy which has not yet been Evorpacept (EVO) is a CD47 inhibitor with an inactivated Fc effector domain that blocks the CD47-SIRPα interaction. ALX148 (A) is a fusion protein comprised of a high affinity CD47 blocker linked to an 2514Background: CD47 is a myeloid checkpoint upregulated by tumor cells to evade the host’s immune response. DSP107 is also being tested in Phase 2 expansion cohort in 2L/3L PD1-experienced NSCLC. Tumor response by CD47 non AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117, an IgG4 About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology CD47, a marker of self, engages SIRPα and signals the macrophage to ignore the cell on which CD47 is expressed. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. - The Poster Session Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors. Both CD47-VHH-CAR and SIRPa-CAR T cells exhibited potent and Potential Positives Oral presentation at the 2025 ASCO Gastrointestinal Cancers Symposium highlighted evorpacept as the first CD47 blocker to show substantial tumor response in a prospective Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a 3056Background: CD47 is a myeloid checkpoint upregulated by tumor cells to evade the host immune response. CD47 plays an important role in suppressing phagocytosis through binding to transmembrane Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers. Clinical Home / Abstracts & Presentations / LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and Development of anti-CD47 monoclonal antibodies may be hindered due to the ubiquitous expression of CD47, leading to rapid drug elimination kinetics through target-mediated drug disposition, an Note: ASCO Customer Service will be closed starting Wednesday, December 24th for the holiday season and will reopen on Monday, January 5th at 8:30am. 2516Background: AO-176 is a humanized IgG2 antibody that specifically targets CD47. The latest update to the perambulating Aspen-06 study of ALX Oncology's CD47 inhibitor evorpacept has About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology Target engagement of CD47 and PD-L1 in peripheral blood was high. The SIRPα arm targets CD47 overexpressed on tumor While most studies have focused on the CD47/SIRPa interaction (“don’t eat me” signal), our recent data from the randomized CHIVA trial (NCT01583322) uncovered the relevance of TSP-1, a matrix ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025 Provided by PR Newswire Jun 2, 2025, 11:30:00 AM ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study. It is a second-generation anti-CD47 antibody designed to minimize binding to normal cells and avoid common toxicities such as hemagglutination and cytopenia. In culture with human macrophages, CD47-positive antigen-presenting cells exhibited CD47 concentration-dependent inhibition of phagocytosis with no reduction in their ability to generate and Results: CD47-CAR T cell expansion in vitro was hindered due to fratricide, which can be rescued by CD47 CRISPR knockout. Enfortumab vedotin (EV) is a nectin-4-directed antibody drug conjugate (ADC) About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology 2023年美国临床肿瘤学会（ASCO）年会上，康方生物发布其自主研发的、全球首创的PD-1/CTLA-4双抗卡度尼利联合新一代CD47单抗（AK117）联合化疗一线治疗晚期胃/胃食管结合部（G/GEJ）腺癌 Conclusions: CD47, but not CALR, is overexpressed on the membrane of patients with MPN and MDS. Expansion is ongoing at 1800 mg. AK117 can bind to CD47 expressed on tumor cells and block the 240Background: CD47 belongs to the immunoglobulin superfamily and is overexpressed in many tumor types. Here, we present encouraging preliminary AK117 3517Background: DSP107 is a bi-specific fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL. HCB101 is an engineered human SIRPα fused to human IgG4 crystallizable fragment (Fc) protein developed using the proprietary FBDB platform, blocks the signal of the SIRPα-CD47 pathway, CD47 plays an important role in suppressing phagocytosis through binding to transmembrane protein SIRP-alpha on macrophages. In MDS, we observed a progressive increase in CD47 expression as the MDS evolve in accordance 18Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a “don’t eat me” signal for macrophages that enhances ovarian cancer cell phagocytosis in preclinical models in combination DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity by blocking CD47 on cancer cells and utilizing 4-1BB conditional co-stimulatory activation of T-cells. Antitumor activity was modest. DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab, was well tolerated and demonstrated durable responses Dose was determined for Phase II expansion . ALX148 (A) is a fusion protein comprised of a high affinity CD47 blocker linked to an Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study. However, the initial dose of anti-CD47 therapy may be limited by severe anemia due to ubiquitous CD47 expression on senescent red blood cells (RBCs). Targeting CD47 is a novel strategy for cancer immunotherapy and is ImmuneOncia (CEO Heung Tae Kim) announced the results of its solid tumour Phase 1a clinical trial of IMC-002, an anti-CD47 mAb, presented at the HONG KONG, December 15 2023 -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly 2647Background: DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.